Effect of Botulinum Toxin type A and Occlusal Splint on Masseter Muscle Evaluated with Computed Tomographic Measurement

전산화 단층촬영으로 평가한 교근에 대한 보툴리눔 A형 독소주사와 교합안정장치의 효과

  • Jang, Hee-Young (Dept. of Oral Medicine, College of Dentistry, Yonsei University) ;
  • Kang, Seung-Chul (Dept. of Oral Medicine, College of Dentistry, Yonsei University) ;
  • Kim, Seong-Taek (Dept. of Oral Medicine, College of Dentistry, Yonsei University) ;
  • Kim, Chong-Youl (Dept. of Oral Medicine, College of Dentistry, Yonsei University) ;
  • Choi, Jong-Hoon (Dept. of Oral Medicine, College of Dentistry, Yonsei University)
  • 장희영 (연세대학교 치과대학 구강내과학 교실) ;
  • 강승철 (연세대학교 치과대학 구강내과학 교실) ;
  • 김성택 (연세대학교 치과대학 구강내과학 교실) ;
  • 김종열 (연세대학교 치과대학 구강내과학 교실) ;
  • 최종훈 (연세대학교 치과대학 구강내과학 교실)
  • Published : 2005.06.30


The purpose of this study is to evaluate the effect of botulinum toxin type A on masseter muscle atrophy and the extent of masseter muscle affected from the injection site in relation to injection dose, with and without occlusal splint therapy through computed tomographic measurement. 32 volunteers were divided into four groups - group 25U (injection dose of 25 unit), group 25Us (injection dose of 25 unit with occlusal splint), group 35U (injection dose of 35 unit), group 35Us (injection dose of 35 unit with occlusal splint). Each group consisted of 8 people. 3 positions (position 1, 2, 3 - 10mm, 20mm and 40mm from the inferior border of the mandible, respectively) were selected for the evaluation of the masseter muscle change. The following results were obtained. 1. The thickness and the cross-sectional area of the masseter muscle had reduced in all groups except for the right side thickness at position 3 of group 25U and group 25Us, and the right side thickness as well as the left side cross-sectional area at position 3 of group 35Us. In group 35Us, the thickness and the cross-sectional area of the masseter muscle had reduced significantly in all positions (P < 0.05). 2. There was no significant difference in the masseter muscle change between the injection dose of 25unit and that of 35unit. 3. The groups with occlusal splint showed greater reduction of the masseter muscle thickness than the other groups (P < 0.05). From the above results, botulinum toxin type A injection together with occlusal splint therapy in the treatment of masseter muscle hypertrophy would be clinically effective.


  1. Legg JW. Enlargement of the temporal and masseter muscle on the both sides. Trans Pathol Soc (Lond) 1880;31:361-366
  2. Gurney CE. Chronic bilateral benign hypertrophy of the masseter muscles. Am J Surg 1947;73:137-139 https://doi.org/10.1016/0002-9610(47)90304-8
  3. Lobbezoo F, Naeije M. Bruxism is mainly regulated centally, not peripherally: J Oral Rehabil 2001;28:1085-1091 https://doi.org/10.1046/j.1365-2842.2001.00839.x
  4. Okeson JP: Orofacial Pain:Guidelines for assessment, diagnosis and management. 1996, pp. 142-158, Quintessence, Chicago
  5. 강원일, 최재갑. 안정교합장치가 교근 및 전측두근 활성에 미치는 영향. 대한구강내과학회지 1991;16:25-32
  6. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991;324:1186-1194 https://doi.org/10.1056/NEJM199104253241707
  7. Burgen AS, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. J Physiol 1949;109:10-24 https://doi.org/10.1113/jphysiol.1949.sp004364
  8. Jankovic J, Brin MF. Botulinum Toxin: historical perspective and potential new indications. Muscle Nerve 1997;20 (suppl 6): S129-S145 https://doi.org/10.1002/(SICI)1097-4598(1997)6+<129::AID-MUS9>3.0.CO;2-B
  9. Smyth AG. Botulinum toxin treatment of bilateral masseteric hypertrophy. Br J Oral Maxillofac Surg 1994;32:29-33 https://doi.org/10.1016/0266-4356(94)90169-4
  10. Moore AP, Wood GD. The medical management of masseteric hypertrophy with botulinum toxin type A. Br J Oral Maxillofac Surg 1994;32:26-28 https://doi.org/10.1016/0266-4356(94)90168-6
  11. von Lindern JJ, Niederhagen B, Appel T, Berge S, Reich RH. Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: an alternative treatment. Plast Reconstr Surg 2001;107:327-332 https://doi.org/10.1097/00006534-200102000-00004
  12. To EW, Ahuja AT, Ho WS, King WW, Wong WK, Pang PC, Hui AC. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. Br J Plast Surg 2001;54:197-200 https://doi.org/10.1054/bjps.2000.3526
  13. Park MY, Ahn KY, Jung DS. Botulinum toxin type A treatment for contouring of the lower face. Dermatol Surg 2003;29:477-483 https://doi.org/10.1046/j.1524-4725.2003.29116.x
  14. Kim HJ, Yum KW, Lee SS, Heo MS, Seo K. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatol Surg 2003;29:484-489 https://doi.org/10.1046/j.1524-4725.2003.29117.x
  15. Christensen LV. Effects of an occlusal splint on intergrated electromyography of masseter muscle in experimental tooth clenching in man. J of Oral Rehabil 1980;7:281-288 https://doi.org/10.1111/j.1365-2842.1980.tb00446.x
  16. Manns A, Miralles R, Cusmsille F. Influence of vertical dimension on masseter muscle electromyographic activity in patients with mandibular dysfuntion. J Prosthet Dent 1985;53:243-247 https://doi.org/10.1016/0022-3913(85)90121-0
  17. Wood WW, Tobias DL. EMG response to alteration of tooth contacts on occlusal splint during maximal clenching. J Prosthet Dent 1984;51:394-396 https://doi.org/10.1016/0022-3913(84)90229-4
  18. Clark GT. A critical evaluation of orthopedic interocclusal appliance theraphy: design, theory, and overall effectiveness. J Am Dent Assoc 1984;108:359-364 https://doi.org/10.14219/jada.archive.1984.0010
  19. Kawazoe Y, Kotani H, Hamada T, Yamada S. Effect of occlusal splints on the electromyographic activities of masseter muscles during maximum clenching in patients with myofascial pain-dysfuntion syndrome. J Prosthet Dent 1980;43:578-580 https://doi.org/10.1016/0022-3913(80)90334-0
  20. Freund B, Schwartz M, Symington JM. The use of botulinum toxin for the treatment of temporomandibular disorders: Preliminary findings. J Oral Maxillofac Surg 1999;57:916-920 https://doi.org/10.1016/S0278-2391(99)90007-1
  21. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For The BOTOX Migraine Clinical Research Group. Headache 2000;40:445-450 https://doi.org/10.1046/j.1526-4610.2000.00066.x
  22. Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000;123:669-676 https://doi.org/10.1067/mhn.2000.110960
  23. Van Zandijcke M, Marchau MM. Treatment of bruxism with botulinum toxin injections. J Neurol Neurosurg Psychiatry 1990;53:530
  24. Ivanhoe CB, Lai JM, Francisco GE. Bruxim after brain injury: Successful treatment with botulinum toxin-A. Arch Phys Med Rehabil 1997;78:1272-1273 https://doi.org/10.1016/S0003-9993(97)90343-9
  25. Pidcock FS, Wise JM, Christensen JR. Treatment of severe post-traumatic bruxism with botulinum toxin-A: Case report. J Oral Maxillofac Surg 2002;60: 115-117 https://doi.org/10.1053/joms.2002.29127